Advertisement

Topics

Sugammadex Hypersensitivity Study (Study P06042)(COMPLETED)

2014-08-27 03:18:57 | BioPortfolio

Summary

This trial is being conducted to study the potential for hypersensitivity symptoms at the time of initial exposure to sugammadex and upon repeat exposure, since it is unknown whether the frequency or severity of hypersensitivity symptoms may worsen at repeat exposure over a prolonged period.

Participants will be randomized to receive one of three study treatments: sugammadex 4 mg/kg, sugammadex 16 mg/kg, or placebo. Participants will receive one dose of study treatment on Day 8, Day 36, and Day 78 of the study in order to determine the safety of each treatment dose.

Description

To ensure safety of the participants, all participants will be admitted to the study center the day before each scheduled dose and will leave the unit the morning of the day after each dose. In cases of suspected hypersensitivity symptoms, participants will remain confined to the study center until all signs and symptoms regress, the participant is stable and the investigator considers it safe for the participant to leave the study center.

Study Design

Allocation: Randomized, Control: Placebo Control, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Conditions

Hypersensitivity

Intervention

Sugammadex 4 mg/kg, Sugammadex 16 mg/kg, Placebo

Status

Completed

Source

Schering-Plough

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:18:57-0400

Clinical Trials [207 Associated Clinical Trials listed on BioPortfolio]

Dose-Finding Pediatric Trial With Sugammadex (19.4.306)(P05961)(COMPLETED)

The purpose of this study is: - to explore the dose-response relation of sugammadex given as a reversal agent at reappearance of T2 after 0.6 mg.kg-1 rocuronium in pediatric and a...

Use of Sugammadex Administered at 5 Minutes After Administration of 1.2 mg/kg Esmeron® (19.4.205)(P05942)(COMPLETED)

The purpose of this study is to determine the optimal dose of sugammadex when this compound is administered during deep neuromuscular block. Sugammadex is administered shortly (5 minutes) ...

Comparison of 4.0 mg/kg Sugammadex at 1-2 PTC in Renal or Control Patients (19.4.328)(P05769AM1)

The current trial was designed to investigate the effects of 4.0 mg.kg-1, of sugammadex on efficacy, safety and pharmacokinetics in subjects with severe renal impairment

Study to Determine if Administration of Sugammadex Impacts Hospital Efficiency

The purpose of this study is to evaluate the efficacy of Sugammadex in rapidly reversing deep neuromuscular blockaded (induced by rocuronium)

Sugammadex ED90 Dose in the Obese Patients

The purpose of this study is to determine the minimum effective dose of sugammadex, an antagonist of neuromuscular blockade used during anesthesia practice, in obese patients, considering ...

PubMed Articles [1171 Associated PubMed Articles listed on BioPortfolio]

Anaphylactic Reactions to Native and Light-Exposed Sugammadex Suggested by Basophil Activation Test: A Report of 2 Cases.

We describe 2 patients who developed anaphylactic shock after sugammadex administration during anesthesia. Both had no history of prior sugammadex administration. The serum tryptase concentrations wer...

Incidence of hypersensitivity and anaphylaxis with sugammadex.

To evaluate the incidence of hypersensitivity and anaphylaxis after administration of sugammadex.

Comparison of postoperative coagulation profiles and outcome for sugammadex versus pyridostigmine in 992 living donors after living-donor hepatectomy.

Donor safety is the major concern in living donor liver transplantation, although hepatic resection may be associated with postoperative coagulopathy. Recently, the use of sugammadex has been graduall...

Effects of magnesium chloride on rocuronium-induced neuromuscular blockade and sugammadex reversal in an isolated rat phrenic nerve-hemidiaphragm preparation: An in-vitro study.

Magnesium potentiates the effects of nondepolarising muscle relaxants. However, few studies have used magnesium chloride (MgCl2). Sugammadex reverses neuromuscular block by steroidal nondepolarising m...

In reply: Is sugammadex alone enough to cause anaphylaxis?

Medical and Biotech [MESH] Definitions

Allergic reaction to products containing processed natural rubber latex such as rubber gloves, condoms, catheters, dental dams, balloons, and sporting equipment. Both T-cell mediated (HYPERSENSITIVITY, DELAYED) and IgE antibody-mediated (HYPERSENSITIVITY, IMMEDIATE) allergic responses are possible. Delayed hypersensitivity results from exposure to antioxidants present in the rubber; immediate hypersensitivity results from exposure to a latex protein.

Antigen-type substances that produce immediate hypersensitivity (HYPERSENSITIVITY, IMMEDIATE).

Epicutaneous or intradermal application of a sensitizer for demonstration of either delayed or immediate hypersensitivity. Used in diagnosis of hypersensitivity or as a test for cellular immunity.

Misunderstanding among individuals, frequently research subjects, of scientific methods such as randomization and placebo controls.

A form of hypersensitivity affecting the respiratory tract. It includes ASTHMA and RHINITIS, ALLERGIC, SEASONAL.

More From BioPortfolio on "Sugammadex Hypersensitivity Study (Study P06042)(COMPLETED)"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Alzheimer's Disease
Of all the types of Dementia, Alzheimer's disease is the most common, affecting around 465,000 people in the UK. Neurons in the brain die, becuase  'plaques' and 'tangles' (mis-folded proteins) form in the brain. People with Al...


Searches Linking to this Trial